Ensign Peak Advisors’s Apellis Pharmaceuticals APLS Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $509K | Hold |
29,397
| – | – | ﹤0.01% | 1551 |
|
|
2025
Q1 | $643K | Sell |
29,397
-49,700
| -63% | -$1.09M | ﹤0.01% | 1468 |
|
|
2024
Q4 | $2.52M | Sell |
79,097
-1,900
| -2% | -$60.6K | ﹤0.01% | 844 |
|
|
2024
Q3 | $2.34M | Sell |
80,997
-2,000
| -2% | -$57.7K | ﹤0.01% | 884 |
|
|
2024
Q2 | $3.18M | Sell |
82,997
-177,277
| -68% | -$6.8M | 0.01% | 757 |
|
|
2024
Q1 | $15.3M | Buy |
260,274
+14,708
| +6% | +$865K | 0.03% | 370 |
|
|
2023
Q4 | $14.7M | Buy |
245,566
+60,000
| +32% | +$3.59M | 0.03% | 351 |
|
|
2023
Q3 | $7.06M | Buy |
185,566
+154,686
| +501% | +$5.88M | 0.02% | 484 |
|
|
2023
Q2 | $2.81M | Buy |
30,880
+950
| +3% | +$86.5K | 0.01% | 759 |
|
|
2023
Q1 | $1.97M | Sell |
29,930
-133,500
| -82% | -$8.81M | ﹤0.01% | 859 |
|
|
2022
Q4 | $8.45M | Buy |
163,430
+141,100
| +632% | +$7.3M | 0.02% | 452 |
|
|
2022
Q3 | $1.53M | Sell |
22,330
-117,829
| -84% | -$8.05M | ﹤0.01% | 883 |
|
|
2022
Q2 | $6.34M | Buy |
140,159
+99,979
| +249% | +$4.52M | 0.02% | 475 |
|
|
2022
Q1 | $2.04M | Sell |
40,180
-45,409
| -53% | -$2.31M | ﹤0.01% | 881 |
|
|
2021
Q4 | $4.05M | Buy |
85,589
+82,647
| +2,809% | +$3.91M | 0.01% | 727 |
|
|
2021
Q3 | $97K | Sell |
2,942
-43,821
| -94% | -$1.44M | ﹤0.01% | 1799 |
|
|
2021
Q2 | $2.96M | Buy |
46,763
+4,062
| +10% | +$257K | 0.01% | 896 |
|
|
2021
Q1 | $1.83M | Hold |
42,701
| – | – | ﹤0.01% | 1158 |
|
|
2020
Q4 | $2.44M | Buy |
42,701
+7,656
| +22% | +$438K | 0.01% | 950 |
|
|
2020
Q3 | $1.06M | Buy |
35,045
+10,495
| +43% | +$317K | ﹤0.01% | 1291 |
|
|
2020
Q2 | $802K | Buy |
24,550
+16,855
| +219% | +$551K | ﹤0.01% | 1345 |
|
|
2020
Q1 | $206K | Sell |
7,695
-2,533
| -25% | -$67.8K | ﹤0.01% | 1528 |
|
|
2019
Q4 | $314K | Buy |
+10,228
| New | +$314K | ﹤0.01% | 1587 |
|